Although C-reactive protein may be a marker of inflammation rather than part of the causal pathway between inflammation and cardiovascular disease,56 randomized clinical trials have shown the efficacy of anti-inflammatory drugs in reducing the risk of cardiovascular events in secondary cardiovascular prevention.7,8,9. The gene discussed is CRP; the disease is cardiovascular disorder.